A PRospective, rAndomizEd Comparison of subcuTaneOous and tRansvenous ImplANtable Cardioverter Defibrillator Therapy
A PRospective, rAndomizEd Comparison of subcuTaneOous and tRansvenous ImplANtable Cardioverter Defibrillator Therapy
This randomized controlled trial will outline the advantages and disadvantages of the
 subcutaneous implantable cardioverter defibrillator (ICD) compared to the transvenous ICD.
Background of the study: The use of implantable cardioverter defibrillators (ICDs) is an
 established therapy for the prevention of death from ventricular arrhythmia. Recently a new
 subcutaneous ICD has been introduced, eliminating the need for transvenous lead placement in
 or on the heart which is mandatory in the transvenous ICD. The new subcutaneous ICD therapy
 already proved to be feasible and safe and is an approved therapy in Europe. It is likely
 that the eliminated need for transvenous lead placement substantially reduces the
 implantation related complications and elongates lead longevity and thus reduces
 inappropriate shocks associated with lead fractures. On the other hand it is unclear whether
 the lack of capability to provide antitachy-pacing (ATP) in the subcutaneous ICD may be a
 limitation for patients with frequent recurrent ventricular tachycardia. This randomized
 controlled trial will outline the advantages and disadvantages of the subcutaneous ICD.

 Objectives of the study: (1) To compare the subcutaneous ICD to the transvenous ICD for major
 adverse events (i.e. inappropriate shocks, acute and chronic implant related complications
 and lead- or device related complications). (2) To determine to which degree the lack of ATP
 function leads to more appropriate shocks in patients with a subcutaneous ICD.

 Study design: Multicenter, prospective, randomized controlled trial with either treatment
 with the transvenous ICD or subcutaneous ICD (1:1).

 Study population: 2x425 patients with class I or IIa indication for ICD therapy without an
 indication for pacing.
Inclusion Criteria:

 -  Patients 18 years and older

 -  Patients with class I or IIa indication for ICD therapy according to the ACC/AHA/ESC
 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the
 Prevention of Sudden Cardiac Death

 Exclusion Criteria:

 -  Patients with documented therapy refractory monomorphic ventricular tachycardia

 -  Patients having an indication for pacing therapy

 -  Patients with ventricular tachycardia less than 170 bpm

 -  Patients failing appropriate QRS/T-wave sensing with the S-ICD ECG patient screening
 tool provided by Cameron Health/Boston Scientific

 -  Patients with incessant ventricular tachycardia

 -  Patients with a serious known concomitant disease with a life expectancy of less than
 one year

 -  Patients with circumstances that prevent follow-up (no permanent home or address,
 transient, etc.)

 -  Patients who have had a previous ICD implant

 -  Patient who receive cardiac contractility modulation therapy or are likely to receive
 cardiac contractility modulation therapy.

 -  Patients who are unable to give informed consent